Our results showed that patients with detectable baseline plasma EGFR-activating mutations had a shorter PFS and OS compared to those without, suggesting that the absence of detectable EGFR-activating mutations in baseline plasma might be used as an indicator for low distant spreading activities and low systemic tumor burden in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.